In the past week, PDSB stock has gone down by -0.61%, with a monthly decline of -29.30% and a quarterly plunge of -33.40%. The volatility ratio for the week is 8.35%, and the volatility levels for the last 30 days are 8.34% for PDS Biotechnology Corporation The simple moving average for the past 20 days is -21.09% for PDSB’s stock, with a -36.28% simple moving average for the past 200 days.
Is It Worth Investing in PDS Biotechnology Corporation (NASDAQ: PDSB) Right Now?
The 36-month beta value for PDSB is also noteworthy at 1.75. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PDSB is 34.89M, and at present, short sellers hold a 17.63% of that float. The average trading volume of PDSB on April 11, 2024 was 918.66K shares.
PDSB) stock’s latest price update
PDS Biotechnology Corporation (NASDAQ: PDSB) has seen a rise in its stock price by 3.81 in relation to its previous close of 3.15. However, the company has experienced a -0.61% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-27 that PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
Analysts’ Opinion of PDSB
Many brokerage firms have already submitted their reports for PDSB stocks, with B. Riley Securities repeating the rating for PDSB by listing it as a “Buy.” The predicted price for PDSB in the upcoming period, according to B. Riley Securities is $10 based on the research report published on November 01, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PDSB reach a price target of $25. The rating they have provided for PDSB stocks is “Overweight” according to the report published on June 28th, 2021.
H.C. Wainwright gave a rating of “Buy” to PDSB, setting the target price at $6 in the report published on November 10th of the previous year.
PDSB Trading at -34.37% from the 50-Day Moving Average
After a stumble in the market that brought PDSB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.16% of loss for the given period.
Volatility was left at 8.34%, however, over the last 30 days, the volatility rate increased by 8.35%, as shares sank -30.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.50% lower at present.
During the last 5 trading sessions, PDSB rose by +0.91%, which changed the moving average for the period of 200-days by -37.59% in comparison to the 20-day moving average, which settled at $4.07. In addition, PDS Biotechnology Corporation saw -34.21% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PDSB
The total capital return value is set at -0.94. Equity return is now at value -122.46, with -62.97 for asset returns.
Based on PDS Biotechnology Corporation (PDSB), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -1.42. The debt to equity ratio resting at 0.91. The interest coverage ratio of the stock is -20.81.
Currently, EBITDA for the company is -42.99 million with net debt to EBITDA at 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.33.
Conclusion
In summary, PDS Biotechnology Corporation (PDSB) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
